Onderzoeker
Bart Claes
- Disciplines:Morfologische wetenschappen, Oncologie
Affiliaties
- Laboratorium voor Translationele Genetica (VIB-KU Leuven) (Afdeling)
Lid
Vanaf1 jan 2012 → 31 jul 2012
Publicaties
1 - 10 van 15
- Identification and functional study of a VEGFR-1 locus predicting bevacizumab treatment outcome(2012)
Auteurs: Bart Claes, Diether Lambrechts, Peter Carmeliet
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials(2012)
Auteurs: Diether Lambrechts, Bart Claes, Joke Reumers, Max Mazzone, Betul Yesilyurt, Roland Devlieger, Chris Verslype, Sabine Tejpar, Hans Wildiers, Peter Carmeliet, et al.
Pagina's: 724 - 733 - MOLECULAR CHARACTERIZATION OF EARLY-STAGE HER2-OVEREXPRESSING BREAST CANCER (HER2+BC) TREATED WITH ADJUVANT TRASTUZUMAB: IDENTIFICATION OF PROGNOSTIC GROUPS(2012)
Auteurs: D Fumagalli, Diether Lambrechts, Patrick Neven, Joke Vanderhaegen, Bart Claes, SK Singhal, M Piccart, S Michiels, C Sotiriou, S Loi
Pagina's: 21 - 21 - Comprehensive mutation analysis in colorectal flat adenomas(2012)
Auteurs: Bart Claes, Diether Lambrechts
- Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs(2011)
Auteurs: Ann Smeets, Anneleen Daemen, Isabelle Vanden Bempt, Olivier Gevaert, Bart Claes, Hans Wildiers, Diether Lambrechts, Bart De Moor, Patrick Neven, Robert Paridaens, et al.
Pagina's: 767 - 776 - Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium(2011)
Auteurs: Diether Lambrechts, Bart Claes, Patrick Neven, Hans Wildiers
Pagina's: 3289 - 3303 - Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial(2011)
Auteurs: Bart Claes, Diether Lambrechts
Pagina's: 2103 - 14 - Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis(2010)
Auteurs: Wendy De Roock, Bart Claes, Eric Van Cutsem, Diether Lambrechts, Sabine Tejpar
Pagina's: 753 - 762 - Pharmaco-epigenomics: Discovering Therapeutic Approaches and Biomarkers for Cancer Therapy(2010)
Auteurs: Bart Claes, Diether Lambrechts
Pagina's: 152 - 160 - Predictors of Benefit in Colorectal Cancer Treated With Cetuximab: Are We Getting "Lost in TranslationAL"? Reply(2010)
Auteurs: Bart Jacobs, Wendy De Roock, Bart Claes, Sabine Tejpar
Pagina's: E175 - E176